论文部分内容阅读
急性淋巴细胞性白血病(急淋)目前采用联合化疗,缓解率有明显的提高,患者的寿命延长。但是,不同患者应用同样化疗,而结果并不相同。个体的差异对疗效的好坏明显有关,并已发现有不少可能影响预后的因素。本文对近五年中住院确诊为急淋
Acute lymphoblastic leukemia (acute lymphoblastic) currently using combination chemotherapy, the response rate was significantly improved, the patient’s life expectancy increased. However, different patients apply the same chemotherapy and the results are not the same. Individual differences are clearly related to the efficacy of the effect, and has found that there are many factors that may affect the prognosis. This article in the past five years in hospital diagnosed as acute lymph node